Please provide your email address to receive an email when new articles are posted on . Patients who achieved enthesitis resolution were more likely to have improvements in pain and physical function.

Please provide your email address to receive an email when new articles are posted on . The FDA has approved secukinumab for the treatment of active psoriatic arthritis in patients aged 2 years and ...

GRAPPA published treatment recommendations for PsA in 2009 based on evidence from systematic reviews and consensus of 70 rheumatologists and dermatologists with subspecialty expertise in management of ...

Psoriatic arthritis (PsA) is an inflammatory disease marked by its multi-domain involvement, from the peripheral and axial joints, skin and nails, enthesitis, eyes, and digits. 1 This complex ...

VIENNA — The investigational interleukin (IL)-17 inhibitor izokibep hit its mark when it came to improving overall disease activity in people with active psoriatic arthritis (PsA) in a phase 2b/3 ...

"The contribution of ultrasound to the understanding of the pathophysiology of PsA and improving the accuracy of diagnosis is invaluable." — Ari Polachek, MD, Tel Aviv University PsA commonly ...

The approval was based on data from 2 pivotal phase 3 studies, which compared Skyrizi to placebo in adults with active PsA who had an inadequate response or were intolerant to biologic therapy and/or ...

psoriasis on the elbow Researchers evaluated the clinical characteristics, disease burden, and treatment of patients with peripheral spondyloarthritis with and without psoriasis. In patients with ...